Nexgel, Inc · NASDAQ:NXGL
Nexgel — Investor Presentation (March 2025)
18 slides from Nexgel's investor presentation, Mar 25, 2025
Slide 1: Investor Presentation March 2025
@NEXCEL @ NEXGEL advanced hydrogel solutions Investor Presen March 2025 NASDAQ: NXGL
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation contains certain forward-looking statements, including those relating to the Company's product development, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and
Slide 3: NEXGEL - Who We Are and What We Do
Agreements with Multi-Billion NEXGEL - Who We Are and What We Do After two decades of creating custom hydrogel solutions for large medical device companies, our Dollar Corporations business today includes the development of ae STADA ; —~_ CINTAS. READY FOR THE WORKDAY* patented medical devices, cust
Slide 4: Multiple Products & Applications for Nexgel's Technology
Multiple Products & Applications for Nexgel’s Technology sovoned ope seen Medical Device NEXGEL is addressing the importance of skin integrity and overall skincare with a medical device licensing model Custom & White Label Bringing proven medical-grade technology to OTC and Beauty & Cosmetics for th
Slide 5: Competitive Advantage: State-of-the-Art Manufacturing Facilities in NA
Competitive Advantage: 1 of 2 State-of-the-Art Manufacturing Facilities in NA Medical grade technology and facility, providing gels to multi-national device companies for over 20 years with sufficient capacity to fulfill consumer and healthcare segments 1 of 2 manufacturing facilities 16,500-square-
Slide 6: Converting and Packaging Facility
Converting and Packaging Facility 50% ownership in converting and packaging business in Granbury, Texas + Significant synergies which enable the onboarding of potential finished goods customers along with enhanced combined marketing and outreach efforts * Increased square footage and installed cutti
Slide 7: Hydrogels for Consumer and Medical Applications
Hydrogels for Consumer and Medical Applications * Electron beam technology eliminates the need for harmful chemicals in cross-linking, which, along with our paraben-free formulation, makes our patches the only option for many medical device applications and preferred among consumers * Gentle formula
Slide 8: Current Medical Device Pipeline
Current Medical Device Pipeline Addressing the importance of skin integrity and overall skincare with a medical device @NEXCEL NASDAQ: NXGL
Slide 9: Medical Device Pipeline: Drug Delivery
Medical Device Pipeline: Drug Delivery Potential for Multiple Drug Delivery Applications through Unique Hydrogel Technology Drug Delivery: Diclofenac Patch To treat short-term pain due to preclinical sprains and bruises Drug Delivery: Apremilast Patch conor vlivmn from NEXGEL Patch After BHours To t
Slide 10: Consumer Health & Beauty
Consumer Health & Beauty Bringing proven medical-grade technology to OTC and B&C for the first time through many new consumer products & applications @NEXGEL NASDAQ: NXGL
Slide 11: NEXGEL Branded Products
NEXGEL Branded Products NOW PARABEN-FREE HISTASOLV oO ~ SilverSeal 4 NASDAQ: NXGL “9
Slide 12: M&A Strategy: Consumer Brand Acquisition
M&A Strategy: Consumer Brand Acquisition Kenkoderm Skincare Line Silly George Beauty Brand + Acquisition completed in December 2023 * Acquisition completed in May 2024 - Complimentary line of alternative psoriasis treatments * Specialty eye and eyelash consumer product line - Profitable (ttm) and im
Slide 13: Cintas Corporation
Cintas Corporation Cintas is a leading provider of corporate identify uniforms, first aid and safety products and services to over 1 million businesses across North America * Cintas will distribute SilverSeal, NEXGEL’s hospital-grade dressing for wounds and burns to its customers in many sectors inc
Slide 14: STADA Arzneimittel AG
STADA Arzneimittel AG Partnership with European leader in consumer health supports expansion of NEXGEL OTC product portfolio STADA focuses on consumer healthcare products, generics and specialty pharm, selling products in approximately 120 countries across the world and this partnership will provide
Slide 15: AbbVie
AbbVie (NYSE: ABBV) CG Converting and Packaging is the exclusive supplier of gel pads to be used with AbbVie’s Rapid Acoustic Pulse device for the improvement in the appearance of cellulite : Allergan Aesthetics, acquired by AbbVie, purchased Soliton, the owner of the Resonic technology, for $550 mi
Slide 16: Reduction of Harmful Carcinogenic Plume from Laser Hair Removal
Reduction of Harmful Carcinogenic Plume from Laser Hair Removal ¢ IRB study in accordance with FDA designed to measure the efficacy of NEXGEL’s hydrogel during laser hair removal in eliminating harmful particles or plume during treatments. * 30-patient human trial at the Florida Clinical Research Ce
Slide 17: Revenue Growth / Record for FY '24 & Q4'24
Revenue Growth / Record for FY ‘24 & Q4'24 $3,000 $2,500 $2,000 $1,500 $1,000 $500 $0 In millions 6 y NEXCEL $1.08M, +110% YOY Q4 2023 $3.04M $2.94M +181% YOY +141% YOY $1.44M $1.27M 423% YOY +104% YOY 2024 Revenue: Q1 2024 Q2 2024 Q3 2024 Q4 2024 NASDAQ: NXGL Highlights: Q4 2024 Revenue: $3.04 mill
Slide 18: Contact Us
Contact Us Investor Relations: KCSA Strategic Communications Valter Pinto, Managing Director PH: (212) 896-1254 NEXGEL@KCSA.com @NEXGEL NASDAQ: NXGL